Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome

PARAMUS, N.J., Aug. 30, 2021 /PRNewswire/ -- Epygenix Therapeutics, Inc. ("Epygenix"), a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the Company's Investigational...

from PR Newswire: https://ift.tt/2Wsznex